RIGEL PHARMACEUTICALS, INC. (RIGL) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $79.39M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.25× | Operating cash flow / net income. Period ending 2026-06-30. $79.39M ÷ $321.91M ≈ 0.25× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 79.39M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 276.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 321.91M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $79.39M | (m) | (m) | $276.79M | (m) | $321.91M | (m) | (m) | (m) | 0.25× |
| 2026-03-31 | (m) | (m) | $79.27M | (m) | (m) | $299.77M | (m) | $364.23M | (m) | (m) | (m) | 0.22× |
| 2025-12-31 | (m) | (m) | $75.66M | (m) | (m) | $294.28M | (m) | $367.02M | (m) | (m) | (m) | 0.21× |
| 2025-09-30 | (m) | (m) | $68.18M | (m) | (m) | $282.08M | (m) | $113.30M | (m) | (m) | (m) | 0.60× |
| 2025-06-30 | (m) | (m) | $65.83M | (m) | (m) | $267.92M | (m) | $97.82M | (m) | (m) | (m) | 0.67× |
| 2025-03-31 | (m) | (m) | $35.59M | (m) | (m) | $203.08M | (m) | $37.18M | (m) | (m) | (m) | 0.96× |
| 2024-12-31 | (m) | (m) | $31.47M | (m) | (m) | $179.28M | (m) | $17.48M | (m) | (m) | (m) | 1.80× |
| 2024-09-30 | (m) | (m) | $10.73M | (m) | (m) | $157.47M | (m) | $3.88M | (m) | (m) | (m) | 2.76× |
| 2024-06-30 | (m) | (m) | $-12.31M | (m) | (m) | $130.30M | (m) | $-14.23M | (m) | (m) | (m) | 0.86× |
| 2024-03-31 | (m) | (m) | $-6.68M | (m) | (m) | $120.35M | (m) | $-19.80M | (m) | (m) | (m) | 0.34× |
| 2023-12-31 | (m) | (m) | $-5.74M | (m) | (m) | $116.88M | (m) | $-25.09M | (m) | (m) | (m) | 0.23× |
| 2023-09-30 | (m) | (m) | $-21.41M | (m) | (m) | $132.37M | (m) | $-24.43M | (m) | (m) | (m) | 0.88× |
| 2023-06-30 | (m) | (m) | $-33.35M | (m) | (m) | $126.64M | (m) | $-37.77M | (m) | (m) | (m) | 0.88× |
| 2023-03-31 | (m) | (m) | $-52.20M | (m) | (m) | $129.58M | (m) | $-44.66M | (m) | (m) | (m) | 1.17× |
| 2022-12-31 | $-74.21M | (m) | $-73.76M | $450.00K | (m) | $120.24M | (m) | $-58.57M | (m) | (m) | -61.72% | 1.26× |
| 2022-09-30 | $-71.29M | (m) | $-70.94M | $356.00K | (m) | $89.37M | (m) | $-82.61M | (m) | (m) | -79.77% | 0.86× |
| 2022-06-30 | $-68.27M | (m) | $-67.93M | $337.00K | (m) | $88.51M | (m) | $-84.53M | (m) | (m) | -77.13% | 0.80× |
| 2022-03-31 | $-584.00K | (m) | $196.00K | $780.00K | (m) | $84.95M | (m) | $-84.86M | (m) | (m) | -0.69% | -0.00× |
| 2021-12-31 | $5.25M | (m) | $5.88M | $627.00K | (m) | $149.24M | (m) | $-17.91M | (m) | (m) | 3.52% | -0.33× |
| 2021-09-30 | $8.24M | (m) | $9.39M | $1.15M | (m) | $147.28M | (m) | (m) | (m) | (m) | 5.59% | (m) |
| 2021-06-30 | $-970.00K | (m) | $207.00K | $1.18M | (m) | $144.12M | (m) | (m) | (m) | (m) | -0.67% | (m) |
| 2021-03-31 | $-69.77M | (m) | $-69.05M | $726.00K | (m) | $133.88M | (m) | (m) | (m) | (m) | -52.12% | (m) |
| 2020-12-31 | $-53.45M | (m) | $-52.19M | $1.26M | (m) | $108.62M | (m) | (m) | (m) | (m) | -49.21% | (m) |
| 2020-09-30 | $-47.63M | (m) | $-46.26M | $1.37M | (m) | $105.57M | (m) | (m) | (m) | (m) | -45.12% | (m) |
| 2020-06-30 | $-42.95M | (m) | $-41.42M | $1.53M | (m) | $108.04M | (m) | (m) | (m) | (m) | -39.75% | (m) |
| 2020-03-31 | $-45.72M | (m) | $-44.03M | $1.69M | (m) | $102.42M | (m) | (m) | (m) | (m) | -44.64% | (m) |
| 2019-12-31 | $-42.97M | (m) | $-41.51M | $1.46M | (m) | $59.29M | (m) | (m) | (m) | (m) | -72.47% | (m) |
| 2019-09-30 | $-21.13M | (m) | $-20.22M | $913.00K | (m) | $81.75M | (m) | (m) | (m) | (m) | -25.85% | (m) |
| 2019-06-30 | $-26.38M | (m) | $-25.66M | $717.00K | (m) | $65.75M | (m) | (m) | (m) | (m) | -40.11% | (m) |
| 2019-03-31 | $-37.29M | (m) | $-36.00M | $1.29M | (m) | $57.13M | (m) | (m) | (m) | (m) | -65.26% | (m) |
| 2018-12-31 | $-59.93M | (m) | $-58.83M | $1.11M | (m) | $44.51M | (m) | (m) | (m) | (m) | -134.65% | (m) |
| 2018-09-30 | $-91.28M | (m) | $-90.19M | $1.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-88.70M | (m) | $-87.71M | $990.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-80.51M | (m) | $-80.19M | $320.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-77.72M | (m) | $-77.56M | $164.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-70.42M | (m) | $-70.31M | $117.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-75.58M | (m) | $-75.27M | $313.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-74.75M | (m) | $-74.23M | $524.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-76.69M | (m) | $-75.89M | $804.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-78.15M | (m) | $-77.22M | $932.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-65.09M | (m) | $-64.11M | $987.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-64.66M | (m) | $-63.82M | $835.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-23.96M | (m) | $-23.41M | $546.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-25.23M | (m) | $-24.62M | $612.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-33.80M | (m) | $-33.54M | $265.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-35.60M | (m) | $-35.34M | $267.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-70.17M | (m) | $-69.75M | $413.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-74.02M | (m) | $-73.59M | $427.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-76.55M | (m) | $-76.00M | $549.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-78.10M | (m) | $-77.38M | $723.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-87.28M | (m) | $-86.06M | $1.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $-90.38M | (m) | $-88.73M | $1.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-89.52M | (m) | $-87.61M | $1.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-89.51M | (m) | $-87.03M | $2.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-88.57M | (m) | $-85.19M | $3.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $-85.25M | (m) | $-82.29M | $2.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-78.60M | (m) | $-75.46M | $3.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-74.90M | (m) | $-71.89M | $3.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-71.68M | (m) | $-69.38M | $2.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $43.18M | (m) | $46.74M | $3.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-102.92M | (m) | $-102.78M | $141.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |